How does codeine metabolism variability affect analgesic outcomes?

How does codeine metabolism variability affect analgesic outcomes?

• A. Codeine metabolism is uniform across individuals, producing consistent analgesia.
• B. Depending on CYP2D6, codeine may be weakly analgesic or excessively potent; genetic variation leads to poor or ultra-rapid metabolism.
• C. CYP2D6 status only affects adverse events, not analgesia.
• D. Codeine is never used for analgesia.

Answer: (B)

Codeine must be converted into morphine to produce meaningful pain relief, so its analgesic effect depends on how a person metabolizes it. The key player is the enzyme CYP2D6, which varies genetically among individuals. Some people are poor metabolizers with little CYP2D6 activity, so little morphine is formed and analgesia is weak. Others are ultra-rapid metabolizers with high CYP2D6 activity, leading to rapid and extensive morphine production and a higher risk of opioid toxicity, including serious respiratory depression. Normal or intermediate metabolizers fall somewhere in between, with typical analgesia but still subject to variability. This genetic difference explains why codeine can be unpredictably effective or unsafe across different people.

Codeine must be converted into morphine to produce meaningful pain relief, so its analgesic effect depends on how a person metabolizes it. The key player is the enzyme CYP2D6, which varies genetically among individuals. Some people are poor metabolizers with little CYP2D6 activity, so little morphine is formed and analgesia is weak. Others are ultra-rapid metabolizers with high CYP2D6 activity, leading to rapid and extensive morphine production and a higher risk of opioid toxicity, including serious respiratory depression. Normal or intermediate metabolizers fall somewhere in between, with typical analgesia but still subject to variability. This genetic difference explains why codeine can be unpredictably effective or unsafe across different people.